<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899364</url>
  </required_header>
  <id_info>
    <org_study_id>GIPS-IV</org_study_id>
    <secondary_id>2015-001006-34</secondary_id>
    <nct_id>NCT02899364</nct_id>
  </id_info>
  <brief_title>Sodium Thiosulfate to Preserve Cardiac Function in STEMI</brief_title>
  <acronym>GIPS-IV</acronym>
  <official_title>Groningen Intervention Study for the Preservation of Cardiac Function With Sodium Thiosulfate After ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Timely and effective reperfusion by primary percutaneous coronary intervention
      (PPCI) is currently the most effective treatment of ST-segment elevation myocardial
      infarction (STEMI). However, permanent myocardial injury related to the ischemia and
      subsequent reperfusion is observed in the vast majority (88%) of patients and harbours a risk
      of heart failure development. Administration of hydrogen sulfide (H2S) has been shown to
      protect the heart from &quot;ischemia reperfusion injury&quot; in various experimental models. Data in
      humans suggests that the H2S-releasing agent sodium thiosulfate (STS) can be administered
      safely.

      Objective: to evaluate the efficacy and safety of STS compared to placebo treatment on
      myocardial infarct size in patients presenting with STEMI and treated with PCI

      Study design: a single centre, double blind, randomized controlled clinical trial. A total of
      380 patients, aged 18 years and above, undergoing primary PCI for a first STEMI and deemed
      amenable, by the investigator, to be treated with STS 12.5g intravenously (i.v.) or matched
      placebo immediately after arrival at the catheterization laboratory (cath-lab) and a repeated
      dose administered 6 hours after the first dose, on top of standard treatment. Primary
      endpoint is infarct size as measured with cardiac magnetic resonance imaging (CMR-imaging) 4
      months after randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction and rationale:

      Despite the recent advances in treatment, acute myocardial infarction (AMI) frequently
      results in permanent myocardial injury imposing an increased risk for adverse cardiac
      remodelling, diminished cardiac function and the development of heart failure. Decreased
      cardiac function after PPCI is associated with impaired prognosis. In addition to PPCI,
      cornerstones pharmacological treatment of myocardial infarction (MI) includes; (1) treatment
      direct against blood coagulation with platelet aggregation inhibitors, (2) cholesterol
      lowering treatment with statins; (3) sympathicus inhibition by beta-blocker treatment; and
      (4) inhibitors of the renin-angiotensin-aldosterone system. These therapies were successfully
      implemented over the last decades and resulted in substantial improvements of prognosis after
      AMI.

      Although timely PPCI has a tremendous benefit in AMI, not only ischemia but also reperfusion
      itself is considered to cause myocardial injury and cardiomyocyte death. This phenomena is
      referred to as &quot;ischemia reperfusion injury&quot; in literature and is caused by the sudden
      restoration of blood flow and its accompanying intracellular acidity (pH) change and calcium
      overload, cardiomyocyte hypercontracture, myocardial inflammation, oxidative stress
      generation and mitochondrial permeability transition pore opening. Reducing ischemia
      reperfusion injury is expected to further decrease infarct size, decreasing adverse cardiac
      remodelling and improving cardiac function as well as clinical outcome.

      The investigators expect a substantial beneficial effect of H2S in the prevention of ischemia
      reperfusion injury. H2S is the third endogenous gaseous transmitter next to carbon monoxide
      (CO) and nitric oxide (NO) and is involved as a physiological mediator in several body organ
      and tissue processes. H2S is synthesized endogenously by enzymatic and non-enzymatic
      pathways. A non-enzymatic pathway is by the reductive reaction with thiosulfate, with
      pyruvate acting as a hydrogen donor. Thiosulfate itself acts as an intermediate in the sulfur
      metabolism of cysteine and is known as a metabolite of H2S and in that way also able to
      produce H2S, especially under hypoxic conditions.

      H2S has been shown to protect from myocardial ischemia reperfusion injury in various
      experimental animal models; e.g. it reduces infarct size and apoptosis and attenuates cardiac
      function. Inhibition of leukocyte endothelial cell interactions, neutralization of reactive
      oxygen species (ROS) and the reduction of apoptotic signalling are the suggested as
      additional mechanisms underlying the cardioprotective effect of H2S. H2S has been shown to
      attenuate myocardial ischemia reperfusion in cellular, rodents and porcine animal models. H2S
      can be safely administered intravenously as STS to humans. STS has been demonstrated to
      detoxify cyanide poisoning in 1895 in dogs, is used in humans since 1933 for the treatment of
      cyanide intoxication, is used since the eighties for treatment of vascular calcifications in
      end-stage renal disease, and is used to prevent toxicity of cisplatin treatment. More
      recently, studies have shown STS can delay the progression of coronary artery calcification
      in haemodialysis patients. The aim of the GIPS-IV trial is to evaluate the efficacy and
      safety of STS compared to placebo treatment on myocardial infarct size in patients presenting
      with STEMI undergoing PPCI in a double blind randomized controlled clinical trial.

      Study design:

      The GIPS-IV trial is a single-centre, prospective, randomized, placebo-controlled, double
      blind trial. A total of 380 patients presenting with a first STEMI will be included. All
      patients will be randomly assigned, in a 1:1 ratio, to receive STS (12.5 mg iv) or matching
      placebo. Study medication will be administered twice. The first dose of study medication will
      be administered immediately after checking inclusion and exclusion criteria and obtaining
      verbal informed consent at the cath-lab. The second dose of study medication will be
      administered 6 hours later, at the Coronary Care Unit (CCU). The study will take place at the
      University Medical Centre of Groningen (UMCG), a high-volume centre with experience in care
      and research in PPCI of patients with STEMI. The primary endpoint will be based on infarct
      size as measured by late gadolinium enhancement cardiac magnetic resonance imaging (LGE
      CMR)-imaging 4 months after STEMI, a period in which the remodelling of the heart is expected
      to be completed. LGE CMR-imaging is a well-recognized, validated, and highly reproducible
      technique. Total follow-up duration of the GIPS-IV trial is 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size as measured with late gadolinium enhancement cardiac magnetic resonance imaging.</measure>
    <time_frame>4 months after randomization</time_frame>
    <description>Primary efficacy parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction as assessed by late gadolinium enhancement cardiac magnetic resonance imaging.</measure>
    <time_frame>4 months after randomization</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion reserve, assessed with rest and stress cardiac magnetic resonance imaging</measure>
    <time_frame>4 months after randomization</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal prohormone of brain natriuretic peptide (NT pro-BNP) level</measure>
    <time_frame>4 months after randomization</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial haemorrhage as assessed by non-mandatory cardiac magnetic resonance imaging.</measure>
    <time_frame>0-5 days after randomization (during hospitalization)</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction as assessed by non-mandatory cardiac magnetic resonance imaging.</measure>
    <time_frame>0-5 days after randomization (during hospitalization)</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial salvage index as assessed by non-mandatory cardiac magnetic resonance imaging.</measure>
    <time_frame>0-5 days after randomization (during hospitalization)</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction as assessed by non-mandatory cardiac magnetic resonance imaging.</measure>
    <time_frame>0-5 days after randomization (during hospitalization)</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-diastolic volume as assessed by non-mandatory cardiac magnetic resonance imaging.</measure>
    <time_frame>0-5 days after randomization (during hospitalization)</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-systolic volume as assessed by non-mandatory cardiac magnetic resonance imaging.</measure>
    <time_frame>0-5 days after randomization (during hospitalization)</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass as assessed by non-mandatory cardiac magnetic resonance imaging.</measure>
    <time_frame>0-5 days after randomization (during hospitalization)</time_frame>
    <description>Secondary efficacy parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>4 months after randomization and after 2-year follow-up</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined major adverse cardiovascular events</measure>
    <time_frame>4 months after randomization and after 2-year follow-up</time_frame>
    <description>Safety parameter. Includes cardiovascular mortality, re-infarction, re-intervention (any revascularization not planned on index CAG), stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantable cardioverter defibrillator implantation</measure>
    <time_frame>4 months after randomization and after 2-year follow-up</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure or chest pain</measure>
    <time_frame>4 months after randomization and after 2-year follow-up</time_frame>
    <description>Safety parameter. defined as an overnight stay, with different dates for admission and discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enzymatic infarct size as assessed by peak creatinine kinase myocardial band (CK-MB).</measure>
    <time_frame>0-3 days after randomization (during hospitalization)</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health related quality of life: EuroQol EQ-5D-5L</measure>
    <time_frame>0-5 days after randomization (during hospitalization) and at 4 months follow up</time_frame>
    <description>Health related quality of life assessed using the EuroQol EQ-5D-5L.
The EQ-5D-5L has 2 components:
There is a descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, unable/extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.
The users guide gives details of the scoring system: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf</description>
  </other_outcome>
  <other_outcome>
    <measure>General affective status</measure>
    <time_frame>0-5 days after randomization (during hospitalization) and at 4 months follow up</time_frame>
    <description>Assessed with PANAS questionnaire (Positive And Negative Affect Schedule), positive affect score can range from 10 to 50, with higher scores representing higher positive affective state; negative affect score ranges from 10 to 50 with lower scores representing lower levels of negative affect</description>
  </other_outcome>
  <other_outcome>
    <measure>Thrombolysis in myocardial infarction (TIMI) grade flow pre- and post-reperfusion (grade 0-3)</measure>
    <time_frame>peri-PCI-procedure</time_frame>
    <description>Analysis of primary and secondary endpoints according to important risk factors and known medical history collected during routine clinical care for STEMI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in electrocardiographic determinants of myocardial reperfusion</measure>
    <time_frame>Up to 4 months follow-up visit.</time_frame>
    <description>Changes include incidence of new Q waves, ST-segment resolution, persistent ST-deviation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Creatine Kinase (IU/L)</measure>
    <time_frame>0-3 days after randomization (during hospitalization)</time_frame>
    <description>Changes in blood biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Creatine Kinase myocardial band in international units per litre (IU/L)</measure>
    <time_frame>0-3 days after randomization (during hospitalization)</time_frame>
    <description>Changes in blood biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Troponin T in nanogram per millilitre (ng/mL)</measure>
    <time_frame>0-3 days after randomization (during hospitalization)</time_frame>
    <description>Changes in blood biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>N-terminal prohormone of brain natriuretic peptide (NT-ProBNP) in nanogram per litre (ng/L)</measure>
    <time_frame>0-5 days after randomization (during hospitalization)</time_frame>
    <description>Changes in blood biomarkers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sodium thiosulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 gram sodium thiosulfate is given intravenously in two doses of 12.5 gram (50mL) dissolved in 250 ml sodium chloride 0.9%. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15 mL/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he will receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 ml Sodium chloride 0.9%, added to 250ml sodium chloride 0.9% is administered twice. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15ml/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium thiosulfate</intervention_name>
    <description>see description under experimental arm</description>
    <arm_group_label>Sodium thiosulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride 0.9%</intervention_name>
    <description>see description under placebo comparator arm</description>
    <arm_group_label>Sodium chloride 0.9%</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>primary percutaneous coronary intervention</intervention_name>
    <description>Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.</description>
    <arm_group_label>Sodium chloride 0.9%</arm_group_label>
    <arm_group_label>Sodium thiosulfate</arm_group_label>
    <other_name>PPCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cardiac magnetic resonance imaging</intervention_name>
    <description>CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.</description>
    <arm_group_label>Sodium chloride 0.9%</arm_group_label>
    <arm_group_label>Sodium thiosulfate</arm_group_label>
    <other_name>CMR-imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years;

          -  The diagnosis STEMI defined by (1.) chest pain suggestive for myocardial ischemia for
             at least 30 minutes, the time from onset of the symptoms less than 12 hours before
             hospital admission, and (2.) an electrocardiogram (ECG) recording with ST- segment
             elevation of more than 0.1 millivolt (mV) in 2 or more contiguous leads or presence of
             new left bundle branch block;

          -  Symptoms and/or ST-segment deviation should be present (persisting) at time of arrival
             in the cath-lab;

          -  PPCI is being considered as treatment;

          -  Patient is willing to cooperate with follow-up during 2 years.

        Exclusion Criteria:

          -  Prior MI (STEMI/non-STEMI/acute coronary syndrome (ACS), unless maximum troponin T &lt;
             50ng/L.

          -  Known permanent atrial fibrillation;

          -  Prior CABG;

          -  Prior PCI, complicated by periprocedural infarction, unless maximum troponin T &lt; 50
             ng/L;

          -  Known cardiomyopathy;

          -  Previous hospitalization for heart failure;

          -  Active malignancy (requiring chemotherapy, radiation or surgery at the time of
             randomization), except for adequately treated non-melanoma skin cancer or other
             noninvasive or in situ neoplasm (e.g., cervical cancer in situ);

          -  History of chemotherapy;

          -  History of radiotherapy in chest region;

          -  Relieve of symptoms and complete ST-segment resolution prior to arrival at the
             cath-lab;

          -  Presentation with cardiogenic shock (systolic blood pressure &lt;90 mmHg);

          -  Severe hypertension (systolic blood pressure &gt;220 mmHg);

          -  Contraindication for metoclopramide (e.g. Parkison; epilepsy)

          -  Sedated and/or intubated patients;

          -  The existence of a condition with a life expectancy of less than 1 year;

          -  Contraindication for 3 Tesla (T) CMR-imaging (e.g. body weight &gt;250kg; known
             claustrophobia; 3 T magnetic resonance imaging (MRI) incompatible ferromagnetic
             objects in the body, end-stage renal disease);

          -  Pregnancy or breastfeeding women; women of childbearing potential with clinical
             suspicion of possible pregnancy;

          -  A condition which, according to the clinical judgment of the investigator and/or
             treating physician, does not allow the patient to successfully participate in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pim van der Harst, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pim van der Harst, Prof. dr.</last_name>
    <phone>0031503616161</phone>
    <email>p.van.der.harst@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Sophie de Koning, M.D.</last_name>
    <phone>0031503616161</phone>
    <email>m.s.l.y.de.koning@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Treant Scheper Hospital</name>
      <address>
        <city>Emmen</city>
        <state>Drenthe</state>
        <zip>7824 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>R.L. Anthonio, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pim van der Harst, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Sophie de Koning, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Pim van der Harst</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Sodium thiosulfate</keyword>
  <keyword>STEMI</keyword>
  <keyword>Infarct size</keyword>
  <keyword>Cardiac magnetic resonance imaging</keyword>
  <keyword>Hydrogen sulfide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

